Company news
Assembly Biosciences, Inc. news in 2022
Assembly Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 18, 2022
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 13, 2022
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 7, 2022
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
November 3, 2022
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
October 23, 2022
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
October 4, 2022
Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases
August 23, 2022
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
August 8, 2022
Assembly Biosciences Announces Program Reprioritization and Organizational Update
July 19, 2022
Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
June 21, 2022
Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022
June 20, 2022
Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
June 7, 2022
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection
June 5, 2022
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
May 11, 2022
Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022
March 20, 2022
Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights
March 9, 2022
Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference
February 8, 2022
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 6, 2022
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
January 5, 2022
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
January 3, 2022
Decks in 2022
- Technical Presentation (August 2022)
Technical · 43 slides · Aug 31, 2022
- Technical Presentation (July 2022)
Technical · 55 slides · Jul 26, 2022